Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 871689, 11 pages
Clinical Study

Role of Color Doppler Imaging in Early Diagnosis and Prediction of Progression in Glaucoma

1Radiology Department, Ciudad Real General University Hospital, 13005 Ciudad Real, Spain
2Ophthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain
3Radiology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain

Received 22 April 2013; Revised 11 July 2013; Accepted 9 August 2013

Academic Editor: Paolo Fogagnolo

Copyright © 2013 Fatima Jimenez-Aragon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This longitudinal and prospective study analyzes the ability of orbital blood flow measured by color Doppler imaging (CDI) to predict glaucoma progression in patients with glaucoma risk factors. Patients with normal perimetry but having glaucoma risk factors and patients in the initial phase of glaucoma were prospectively included in the study and divided, after a five-year follow-up, into two groups: “Progression” and “No Progression” based on the changes in the Moorfields regression analysis (MRA) classification of Heidelberg retina tomograph (HRT). An orbital CDI was performed in all patients and the parameters obtained were correlated with changes in HRT. A logistic discrimination function (LDF) was calculated for ophthalmic artery (OA) and central retinal artery (CRA) parameters. Receiver operating characteristics curves (ROC) were used to assess the usefulness of LDFs to predict glaucomatous progression. A total of 71 eyes were included. End-diastolic velocity, time-averaged velocity, and resistive index in the OA and CRA were significantly different ( ) between the Progression and No Progression groups. The area under the ROC curves calculated for both LDFs was of 0.695 (OA) and 0.624 (CRA). More studies are needed to evaluate the ability of CDI to perform early diagnosis and to predict progression in glaucoma in eyes.